Catatonia: A narrative review

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 73-79

  Fornaro, Michele ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Catatonia; Neuroleptic malignant syndrome (NMS); Serotonin syndrome (SS)

Indexed keywords

4 AMINOBUTYRIC ACID; AMOBARBITAL; BENZODIAZEPINE; CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; DIAZEPAM; DOPAMINE; LORAZEPAM; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

BEHAVIOR; BRAIN BLOOD FLOW; CATATONIA; DISEASE ASSOCIATION; ELECTROCONVULSIVE THERAPY; FAMILY HISTORY; HUMAN; MEDICAL HISTORY; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SEROTONIN SYNDROME; METABOLISM; PHYSIOLOGY; SYNDROME;

BEHAVIOR; CATATONIA; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMITTER AGENTS; SEROTONIN SYNDROME; SYNDROME;

EID: 79952998546     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152411794961031     Document Type: Review

References (67)

1. Conti, N. A. From alienation to mental illnesses in Germany: Karl Kahlbaum and his thought of change. Vertex, 2008, 19(80), 228-230.
2. Carroll, B. T.; Ramirez, J.; Faiz, K.; Kirkhart, R.; Thomas, C. Regarding catatonia. Psychiatry (Edgmont), 2007, 4(5), 15-16.
3. Kay, S.R.; Kanofsky, D.; Lindenmayer, J.P.; Opler, L.A. The changing presentation of catatonia. Am. J. Psychiatry, 1987, 144 (6), 834-835.
4. Morrison, J.R. Karl Kahlbaum and catatonia. Compr. Psychiatry, 1974, 15(4), 315-316.
5. Mucha, H. The concept of catalepsy from Kahlbaum to the present. Psychiatr Clin (Basel), 1972, 5(6), 330-349.
6. Kendler, K.S. Kraepelin and the differential diagnosis of dementia praecox and manic-depressive insanity. Compr. Psychiatry, 1986, 27(6), 549-558.
7. Fink, M. Catatonia and DSM-IV. Convuls. Ther., 1992, 8(3), 159-162.
8. APA, Diagnostic and Statistical Manual for Mental Disorders, Fourth edition (DSM-IV). Washington, 1994.
9. Francis, A.; Fink, M.; Appiani, F.; Bertelsen, A.; Bolwig, T.G.; Braunig, P.; Caroff, S.N.; Carroll, B.T.; Cavanna, A.E.; Cohen, D.; Cottencin, O.; Cuesta, M.J.; Daniels, J.; Dhossche, D.; Fricchione, G. L.; Gazdag, G.; Ghaziuddin, N.; Healy, D.; Klein, D.; Kruger, S.; Lee, J.W.; Mann, S.C.; Mazurek, M.; McCall, W.V.; McDaniel, W.W.; Northoff, G.; Peralta, V.; Petrides, G.; Rosebush, P.; Rummans, T. A.; Shorter, E.; Suzuki, K.; Thomas, P.; Vaiva, G.; Wachtel, L. Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. J. ECT, 2010, 26(4), 246-247.
10. Bush, G.; Fink, M.; Petrides, G.; Dowling, F.; Francis, A. Catatonia I. Rating scale and standardized examination. Acta Psychiatr. Scand., 1996, 93(2), 129-136.
11. Rosebush, P.I.; Mazurek, M.F. Catatonia and its treatment. Schizophr. Bull., 2010, 36(2), 239-242.
12. Gjessing, L. R.; Harding, G. F.; Jenner, F. A.; Johannessen, N. B. The EEG in three cases of periodic catatonia. Br. J. Psychiatry, 1967, 113(504), 1271-1282.
13. Northoff, G. Brain imaging in catatonia: current findings and a pathophysiologic model. CNS Spectr., 2000, 5(7), 34-46.
14. Northoff, G.; Kotter, R.; Baumgart, F.; Danos, P.; Boeker, H.; Kaulisch, T.; Schlagenhauf, F.; Walter, H.; Heinzel, A.; Witzel, T.; Bogerts, B. Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation. Schizophr. Bull., 2004, 30(2), 405-427.
15. Early, T.S. Asymmetric metabolism over basal ganglia in catatonia. Biol. Psychiatry, 1990, 28(2), 177.
16. Smoller, J.W.; Gardner-Schuster, E.; Misiaszek, M. Genetics of anxiety: would the genome recognize the DSM? Depress. Anxiety, 2008, 25(4), 368-77.
17. Stober, G.; Saar, K.; Ruschendorf, F.; Meyer, J.; Nurnberg, G.; Jatzke, S.; Franzek, E.; Reis, A.; Lesch, K. P.; Wienker, T. F.; Beckmann, H. Splitting schizophrenia: periodic catatoniasusceptibility locus on chromosome 15q15. Am. J. Hum. Genet., 2000, 67(5), 1201-1207.
18. Meyer, J.; Huberth, A.; Ortega, G.; Syagailo, Y. V.; Jatzke, S.; Mossner, R.; Strom, T. M.; Ulzheimer-Teuber, I.; Stober, G.; Schmitt, A.; Lesch, K. P. A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol. Psychiatry, 2001, 6(3), 302-6.
19. Meyer, J.; Mai, M.; Ortega, G.; Mossner, R.; Lesch, K. P. Mutational analysis of the connexin 36 gene (CX36) and exclusion of the coding sequence as a candidate region for catatonic schizophrenia in a large pedigree. Schizophr. Res., 2002, 58(1), 87-91.
20. Stober, G.; Meyer, J.; Nanda, I.; Wienker, T. F.; Saar, K.; Jatzke, S.; Schmid, M.; Lesch, K. P.; Beckmann, H. hKCNN3 which maps to chromosome 1q21 is not the causative gene in periodic catatonia, a familial subtype of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2000, 250(4), 163-168.
21. Northoff, G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J. Neural. Transm., 2002, 109(12), 1453-1467.
22. Van Dalfsen, A. N.; Van Den Eede, F.; Van Den Bossche, B.; Sabbe, B. G. Benzodiazepines in the treatment of catatonia. Tijdschr. Psychiatr., 2006, 48(3), 235-239.
23. Graham, K. T.; Carroll, B. T. Dopamine in catatonia. J. Clin. Psychopharmacol., 2001, 21(6), 624-5.
24. Gonzalez-Vegas, J. A. Antagonism of dopamine-mediated inhibition in the nigro-striatal pathway: a mode of action of some catatonia-inducing drugs. Brain Res., 1974, 80(2), 219-28.
25. Northoff, G.; Eckert, J.; Fritze, J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J. Neurol. Neurosurg. Psychiatry, 1997, 62(4), 404-406.
26. Yeung, P. P.; Milstein, R. M.; Daniels, D. C.; Bowers, M. B., Jr. ECT for lorazepam-refractory catatonia. Convuls. Ther., 1996, 12(1), 31-35.
27. Ditmore, B. G.; Malek-Ahmadi, P.; Mills, D. M.; Weddige, R. L. Manic psychosis and catatonia stemming from systemic lupus erythematosus: response to ECT. Convuls. Ther., 1992, 8(1), 33-37.
28. Weller, M.; Kornhuber, J. Lyell syndrome and lethal catatonia: a case for ECT. Am. J. Psychiatry, 1992, 149(8), 1114.
29. Ali, S.; Welch, C.A.; Park, L.T.; Pliakas, A.M.; Wilson, A.; Nicolson, S.; Huffman, J.; Fricchione, G. L. Encephalitis and catatonia treated with ECT. Cogn. Behav. Neurol., 2008, 21(1), 46-51.
30. Trivedi, H. K.; Mendelowitz, A. J.; Fink, M. Gilles de la Tourette form of catatonia: response to ECT. J. ECT, 2003, 19(2), 115-117.
31. Wachtel, L. E.; Kahng, S.; Dhossche, D. M.; Cascella, N.; Reti, I. M. ECT for catatonia in an autistic girl. Am. J. Psychiatry, 2008, 165(3), 329-33.
32. Balhara, Y. Catatonia or no catatonia: still beyond lorazepam/amobarbital. Am. J. Psychiatry, 2007, 164(3), 525.
33. Munoz, R. A. Neuroleptic malignant syndrome and lethal catatonia. Am. J. Psychiatry, 1987, 144(10), 1369-1370.
34. Mann, S. C.; Caroff, S. N.; Bleier, H. R.; Welz, W. K.; Kling, M. A.; Hayashida, M. Lethal catatonia. Am. J. Psychiatry, 1986, 143(11), 1374-1381.
35. Van Den Eede, F.; Van Hecke, J.; Van Dalfsen, A.; Van den Bossche, B.; Cosyns, P.; Sabbe, B. G. The use of atypical antipsychotics in the treatment of catatonia. Eur. Psychiatry, 2005, 20(5-6), 422-429.
36. Guzman, C. S.; Myung, V. H.; Wang, Y. P. Treatment of periodic catatonia with atypical antipsychotic, olanzapine. Psychiatry Clin. Neurosci., 2008, 62(4), 482.
37. Stemp, L. I. Management of lethal catatonia with dantrolene sodium. Crit. Care Med., 1993, 21(9), 1403.
38. Petursson, H. Lithium treatment of a patient with periodic catatonia. Acta Psychiatr. Scand, 1976, 54(4), 248-253.
39. Desarkar, P.; Das, A.; Das, B.; Sinha, V. K. Lithium toxicity presenting as catatonia in an adolescent girl. J. Clin. Psychopharmacol., 2007, 27(4), 410-412.
40. Smith, M.; Lebegue, B. Lorazepam in the treatment of catatonia. Am. J. Psychiatry, 1991, 148(9), 1265.
41. McEvoy, J. P.; Lohr, J. B. Diazepam for catatonia. Am. J. Psychiatry, 1984, 141(2), 284-285.
42. Benazzi, F. Parenteral clonazepam for catatonia. Can. J. Psychiatry, 1991, 36(4), 312.
43. Francis, A.; Fink, M. ECT response in catatonia. Am. J. Psychiatry, 1992, 149(4), 581-582.
44. Cornic, F.; Consoli, A.; Tanguy, M. L.; Bonnot, O.; Perisse, D.; Tordjman, S.; Laurent, C.; Cohen, D. Association of adolescent catatonia with increased mortality and morbidity: evidence from a prospective follow-up study. Schizophr. Res., 2009, 113(2-3), 233-240.
45. de Entrambasaguas, M.; Sanchez, J. L.; Schonewille, W. Malignant catatonia. Rev. Neurol., 2000, 30(2), 132-138.
46. Reynolds, R. D. Serotonergic drugs and the serotonin syndrome. Am. Fam. Physician, 1994, 49(5), 1083-1086.
47. Sarkar, P.; Natarajan, C.; Gode, N. Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients. Indian J. Psychiatry, 2009, 51(3), 202-205.
48. Adityanjee. The spectrum concept and prevalence of neuroleptic malignant syndrome. Am. J. Psychiatry, 1988, 145(8), 1041.
49. Fido, A. A. Postpartum period: a risk factor for neuroleptic malignant syndrome. Ann. Clin. Psychiatry, 1999, 11(1), 13-15.
50. Yasugi, S.; Garg, V.; Been, G.; Magoulas, P. Neuroleptic malignant syndrome. Aust. N. Z. J. Psychiatry, 2010, 44(6), 584.
51. Akpaffiong, M. J. Risk factors for neuroleptic malignant syndrome. J. Natl. Med. Assoc., 1992, 84(9), 800-202.
52. Kirkpatrick, B.; Edelsohn, G. A. Risk factors for the neuroleptic malignant syndrome. Psychiatr. Med., 1984, 2(4), 371-81.
53. Rasmussen, K. G. Risk factors for neuroleptic malignant syndrome. Am. J. Psychiatry, 1998, 155(11), 1639-1640.
54. Yacoub, A.; Francis, A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr. Dis. Treat., 2006, 2(2), 235-240.
55. Francis, A.; Chandragiri, S.; Rizvi, S.; Koch, M.; Petrides, G. Is Lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr., 2000, 5(7), 54-57.
56. Charra, B.; Nejmi, H.; Hachimi, A.; Benslama, A.; Motaouakkil, S. Neuroleptic malignant syndrome. Ann. Fr. Anesth. Reanim., 2006, 25(5), 542-543.
57. Di Stasi, V. Neuroleptic malignant hyperthermia syndrome. Clin. Ter., 1986, 118(6), 449-452.
58. Dhib-Jalbut, S.; Hesselbrock, R.; Brott, T.; Silbergeld, D. Treatment of the neuroleptic malignant syndrome with bromocriptine. JAMA, 1983, 250(4), 484-485.
59. Daoudai, P.; Delacour, J. L. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet, 1982, 2(8291), 217.
60. Ray, L. T. "Multiple ECT" for neuroleptic malignant syndrome. J. ECT, 1999, 15(4), 284-285.
61. Hilton, S. E.; Maradit, H.; Moller, H. J. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur. Arch. Psychiatry Clin. Neurosci., 1997, 247(3), 113-119.
62. Evans, C. E.; Sebastian, J. Serotonin syndrome. Emerg. Med. J., 2007, 24(4), e20.
63. Can you recognize serotonin syndrome? Nursing, 2006, 36 (5 Suppl E D), 14.
64. Reynolds, R. D. Serotonin syndrome cause and treatment. J. Am. Board Fam. Pract., 1996, 9(1), 73-74.
65. Akiskal, H. S.; Mallya, G. Criteria for the "soft" bipolar spectrum: treatment implications. Psychopharmacol. Bull., 1987, 23(1), 68-73.
66. Kruger, S.; Cooke, R. G.; Spegg, C. C.; Braunig, P. Relevance of the catatonic syndrome to the mixed manic episode. J. Affect. Disord., 2003, 74(3), 279-285.
67. Taylor, M. A.; Fink, M. Catatonia in psychiatric classification: a home of its own. Am. J. Psychiatry, 2003, 160(7), 1233-1241.